Protalix BioTherapeutics (PLX) Share-based Compensation (2010 - 2026)
Protalix BioTherapeutics (PLX) recorded quarterly Share-based Compensation of $532000.0 in Q1 2026, down 27.32% quarter-over-quarter from $732000.0 in Q4 2025, and down 1.48% on a YoY basis from $540000.0 in Q1 2025.
Protalix BioTherapeutics (PLX) Share-based Compensation (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $532000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation fell 1.48% year-over-year to $532000.0; the TTM figure through Mar 2026 stood at $2.3 million (down 18.6% YoY), while the FY2025 annual figure was $2.3 million, down 29.39% from the prior year.
- Share-based Compensation was $532000.0 for Q1 2026 at Protalix BioTherapeutics, down from $732000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.4 million in Q4 2023 to a low of $36000.0 in Q3 2022.
- Historically, Share-based Compensation has averaged $620529.4 across 5 years, with a median of $598000.0 in 2025.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation sank 89.53% in 2022, then jumped 1900.0% in 2023.
- A 5-year view of Share-based Compensation shows it stood at $539000.0 in 2022, then soared by 153.62% to $1.4 million in 2023, then plunged by 52.16% to $654000.0 in 2024, then rose by 11.93% to $732000.0 in 2025, then fell by 27.32% to $532000.0 in 2026.
- The last three Share-based Compensation figures came in at $532000.0 (Q1 2026), $732000.0 (Q4 2025), and $598000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Protalix BioTherapeutics | 176.47 Mn | 165.67 Mn | 29.62 Mn | 532,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 532,000.00 |
| Mar 31, 2026 | 532,000.00 |
| Dec 31, 2025 | 732,000.00 |
| Dec 31, 2025 | 732,000.00 |
| Sep 30, 2025 | 598,000.00 |
| Sep 30, 2025 | 598,000.00 |
| Jun 30, 2025 | 427,000.00 |
| Jun 30, 2025 | 427,000.00 |
| Mar 31, 2025 | 540,000.00 |
| Mar 31, 2025 | 540,000.00 |
| Dec 31, 2024 | 654,000.00 |
| Dec 31, 2024 | 654,000.00 |
| Sep 30, 2024 | 620,000.00 |
| Sep 30, 2024 | 620,000.00 |
| Jun 30, 2024 | 998,000.00 |
| Jun 30, 2024 | 998,000.00 |
| Mar 31, 2024 | 981,000.00 |
| Mar 31, 2024 | 981,000.00 |
| Dec 31, 2023 | 1.37 Mn |
| Dec 31, 2023 | 1.37 Mn |